More Serbia: Molnupiravir Real World Utilization Among COVID-19 Patients in Serbia

Speaker(s)

Nađvinski N1, Liu J2, Liu G2, Stevanović G3, Cvetković A4, Bojat V5, Antić V6, Preveden T7, Jerkan M8, Forés Maresma M9, Cuadras D9, Lynam M9, Arnet U10
1MSD d.o.o., Belgrade, SRB, Serbia, 2Merck & Co. Inc., Rahway, NJ, USA, 3UKC Serbia, Belgrade, -, Serbia, 4Primary health center, Zemum, -, Serbia, 5Primary health center, Novi Sad, -, Serbia, 6Primary health center, Kragujevac, -, Serbia, 7UKC Vojvodina, Vojvodina, -, Serbia, 8Primary health center, Niš, -, Serbia, 9IQVIA, Barcelona, -, Spain, 10MSD Innovation GmbH, Zürich-Airport, ZH, Switzerland

Presentation Documents

OBJECTIVES: Molnupiravir is currently available under an import license which is approved the agency of drugs and medical devices of Serbia (ALIMS), following the decision of the Government of Serbia (СП05:00-566/2021), for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult patients who are at high risk of progression to severe disease. This study describes the patient characteristics and clinical outcomes of molnupiravir users in a real-world setting in Serbia, where molnupiravir has been available since the end of 2021.

METHODS: In this chart review study, non-hospitalized adults (≥18 years) with COVID-19 treated with molnupiravir between January 1 to April 30, 2022 were included from five outpatient health centers. Patients’ characteristics at the time of molnupiravir initiation and clinical outcomes within 28 days after molnupiravir initiation were collected.

RESULTS: In this analysis, 1172 patients were included. Mean age was 57.5 years and 58.2% were female. At the time of molnupiravir initiation,38.5% of the patients had 2 or more co-morbidities, with hypertension (55.9%) and obesity (18.7%) being the most common. The majority (72.4%) had at least one comedication other than molnupiravir and 20.1% had ≥5 comedications. 65.9% received COVID-19 vaccination. Within 28 days of initiating molnupiravir, 4 (0.3%) patients were hospitalized due to COVID-19. Of the hospitalized patients, 3 were older than 60 years, 2 were admitted to an intensive care unit, and one required mechanical ventilation. No death occurred among the patients in our study.

CONCLUSIONS: The current study describes the patient profile and clinical outcomes of individuals treated with molnupiravir in a real-world setting in Serbia. Patient population was on average younger and had fewer co-medications and comorbidities than in other published retrospective studies of molnupiravir-treated patients, reflecting a less restrictive use of the medication in Serbia. Hospitalization was uncommon after treatment with molnupiravir, and no death occurred.

Code

CO162

Topic

Clinical Outcomes, Study Approaches

Topic Subcategory

Clinician Reported Outcomes, Electronic Medical & Health Records

Disease

Drugs, Infectious Disease (non-vaccine), Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)